Williams, Richard T <br/><br/>
Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia.  [electronic resource] 

 -  Proceedings of the National Academy of Sciences of the United States of America  Apr 2006 
 - 6688-93 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0027-8424 
<br/><br/><label>Standard No.: </label>10.1073/pnas.0602030103  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Alleles<br/>Animals<br/>Antineoplastic Agents--pharmacology<br/>B-Lymphocytes--drug effects<br/>Benzamides<br/>Bone Marrow Transplantation<br/>Cyclin-Dependent Kinase Inhibitor p16<br/>Genes, abl<br/>Hematopoietic Stem Cells--drug effects<br/>Humans<br/>Imatinib Mesylate<br/>Interleukin-7--pharmacology<br/>Leukemia, Lymphoid--drug therapy<br/>Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy<br/>Male<br/>Mice<br/>Mice, Inbred C57BL<br/>Mice, Knockout<br/>Neoplasm Transplantation<br/>Piperazines--pharmacology<br/>Pyrimidines--pharmacology<br/>Tumor Cells, Cultured<br/>Tumor Suppressor Protein p14ARF--deficiency